These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 18035916

  • 1. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 2. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [Abstract] [Full Text] [Related]

  • 3. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 5. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [Abstract] [Full Text] [Related]

  • 6. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
    Pathak A, Hanon O, Negre-Pages L, Sevenier F, OSCAR investigators.
    Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
    [Abstract] [Full Text] [Related]

  • 7. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [Abstract] [Full Text] [Related]

  • 8. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
    Teitelbaum I, Chilvers M, Reiz RJ.
    Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
    [Abstract] [Full Text] [Related]

  • 9. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB.
    Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP, Ruffolo RR.
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [Abstract] [Full Text] [Related]

  • 11. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nádházi Z, Petrella R, Sedefdjian A, Sévenier F, Shlyakhto EV, Pathak A.
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [Abstract] [Full Text] [Related]

  • 12. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M, Martínez M, Gabriel F, Guiral V, Ruiz-Aja S, Beltrán B, Muñoz A.
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [Abstract] [Full Text] [Related]

  • 13. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group.
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [Abstract] [Full Text] [Related]

  • 14. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS, McKay DW, Reiz RJ.
    Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [Abstract] [Full Text] [Related]

  • 15. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
    Hedner T.
    J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
    [Abstract] [Full Text] [Related]

  • 16. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
    Drugs Exp Clin Res; 2004 Jun; 30(3):125-32. PubMed ID: 15366789
    [Abstract] [Full Text] [Related]

  • 17. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S, Hammersen F, Kulschewski A, Frerichs A, Frieg R, Hahnheiser D, Reich G, Schnieders M, Schrandt G, Schrader J.
    Dtsch Med Wochenschr; 2006 Nov 17; 131(46):2580-5. PubMed ID: 17096303
    [Abstract] [Full Text] [Related]

  • 18. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC.
    Nat Clin Pract Neurol; 2006 Jan 17; 2(1):24-5. PubMed ID: 16932517
    [No Abstract] [Full Text] [Related]

  • 19. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D, Hill MD.
    Expert Rev Cardiovasc Ther; 2009 May 17; 7(5):459-64. PubMed ID: 19419253
    [Abstract] [Full Text] [Related]

  • 20. Eprosartan: a review of its use in the management of hypertension.
    Robins GW, Scott LJ.
    Drugs; 2005 May 17; 65(16):2355-77. PubMed ID: 16266204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.